menu

KDIGO Conversations in Nephrology: Management of Dyskalemias

Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

KDIGO Conversations in Nephrology: Management of Dyskalemias

close
ReachMD Healthcare Image
Restart
Resume
Read full article
Choose a format
Media formats available:
A pre-test is required to view this content.
A pre-survey is required to view this content.
Details
Presenters
Comments
  • Overview

    Drs. Pecoits-Filho and Herzog explore the challenges that occur when managing dyskalemia. Their conversation addresses consequences of hyperkalemia and hypokalemia. They also discuss how both hospitalized patients and outpatients are affected by acute hyperkalemia.

    This episode is part of the KDIGO Conversations in Nephrology podcast series.
  • Disclosure of Conflicts of Interest

    Roberto Pecoits-Filho, MD, PHD, FACP, FASN, PHD
    Senior Research Scientist
    Arbor Research Collaborative for Health
    Professor of Medicine
    Pontifical Catholic University of Paraná,

    Consulting Fees/Advisory Board: Bayer, AstraZeneca, Akebia, Fibrogen
    Commercial Interest Speakers Bureau: Boehringer Ingelheim, AstraZeneca, Novo Nordisk, Bayer

    Charles Herzog, MD, FACC, FAHA
    Professor of Medicine
    University of Minnesota
    Cardiologist
    Hennepin Healthcare

    Contracted Research: Amgen, AstraZeneca, Bristol-Myers Squibb, NHLBI/NIH, NIDDK/NIH, Relypsa, University of British Columbia
    Ownership Interest: Boston Scientific, Bristol-Myers Squibb, General Electric, Johnson & Johnson
    Royalty: UpToDate 
    Consulting Fees/Advisory Board: Abbvie, Amgen, AstraZeneca, Bayer, Corvidia, Diamedica, FibroGen, Janssen, National Heart Lung and Blood Institute (NHLBI/NIH), NxStage, Pfizer, Relypsa, Sanifit, and University of Oxford

  • Provider(s)/Educational Partner(s)

    This episode is jointly provided by KDIGO and Medtelligence

    ReachMD Healthcare ImageReachMD Healthcare Image

  • Commercial Support

    This episode is supported by Vifor Pharma.

Facebook Comments

Recommended
Details
Presenters
Comments
  • Overview

    Drs. Pecoits-Filho and Herzog explore the challenges that occur when managing dyskalemia. Their conversation addresses consequences of hyperkalemia and hypokalemia. They also discuss how both hospitalized patients and outpatients are affected by acute hyperkalemia.

    This episode is part of the KDIGO Conversations in Nephrology podcast series.
  • Disclosure of Conflicts of Interest

    Roberto Pecoits-Filho, MD, PHD, FACP, FASN, PHD
    Senior Research Scientist
    Arbor Research Collaborative for Health
    Professor of Medicine
    Pontifical Catholic University of Paraná,

    Consulting Fees/Advisory Board: Bayer, AstraZeneca, Akebia, Fibrogen
    Commercial Interest Speakers Bureau: Boehringer Ingelheim, AstraZeneca, Novo Nordisk, Bayer

    Charles Herzog, MD, FACC, FAHA
    Professor of Medicine
    University of Minnesota
    Cardiologist
    Hennepin Healthcare

    Contracted Research: Amgen, AstraZeneca, Bristol-Myers Squibb, NHLBI/NIH, NIDDK/NIH, Relypsa, University of British Columbia
    Ownership Interest: Boston Scientific, Bristol-Myers Squibb, General Electric, Johnson & Johnson
    Royalty: UpToDate 
    Consulting Fees/Advisory Board: Abbvie, Amgen, AstraZeneca, Bayer, Corvidia, Diamedica, FibroGen, Janssen, National Heart Lung and Blood Institute (NHLBI/NIH), NxStage, Pfizer, Relypsa, Sanifit, and University of Oxford

  • Provider(s)/Educational Partner(s)

    This episode is jointly provided by KDIGO and Medtelligence

    ReachMD Healthcare ImageReachMD Healthcare Image

  • Commercial Support

    This episode is supported by Vifor Pharma.

Facebook Comments

Schedule19 Oct 2021